Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
BURLINGTON, Mass., Oct. 16, 2017 -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its third quarter 2017 financial results on Thursday, October 26, 2017, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook.
Access to the live call is available by dialing 844-239-5284 (+1-512-961-6497 for international callers), passcode 99745674. The call can also be accessed live or via replay through a webcast at www.lemaitre.com/investor.
About LeMaitre Vascular
LeMaitre Vascular is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. The Company's diversified product portfolio consists of brand name devices used in arteries and veins outside of the heart. Additional information can be found at www.lemaitre.com.
LeMaitre and the LeMaitre Vascular logo are registered trademarks of LeMaitre Vascular, Inc.
LeMaitre Vascular, Inc.
Steven Chehames
Investor Relations
+1-781-425-1659
[email protected]
http://www.lemaitre.com
